Antisense 1 items

Trials, agents, guidance

• Agent Pelacarsen (TQJ230, AKCEA-APO(a)-LRx)Phase 3; first phase 3 result July 2026 (apheresis trial); outcomes trial Lp(a)HORIZON awaited